An Open Label Study of the Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

Trial Profile

An Open Label Study of the Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Pegunigalsidase alfa (Primary)
  • Indications Fabry's disease
  • Focus Adverse reactions; Registrational
  • Acronyms BRIDGE
  • Sponsors Protalix Biotherapeutics
  • Most Recent Events

    • 22 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 06 Jun 2016 Results from this trial will support regulatory filings in the US and European Union, according to a Protalix BioTherapeutics media release.
    • 09 May 2016 According to a Protalix BioTherapeutics media release, this trial is expected to initiate in mid-2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top